Europe from an outside perspective but also from within, is very complex. But as in the US, there is a certain concentration of Biotechnology and Pharma activity in specific clusters. This session will provide an overview and comparison of what’s happening in Europe regarding Venture Capital Investments, development of therapeutic pipelines and number of companies. The new report by KPMG and Venture Valuation “Site Selection in Europe 2018” will be presented. The short presentation of the report will be followed by a panel discussion with key stakeholders of the European Biotech Industry to discuss the state of the industry and future developments.
Session ID: 425182